ENDURE: ONS Symposium May 5th 2017
May 5, 2017
The goal of this educational activity to improve healthcare providers’ knowledge of a new novel treatment strategy for patients with breast cancer.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review current research on the use of CDK 4/6 inhibitors for breast cancer patients, including pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
- Discuss the MOA of CDK 4/6 inhibitors
- Review clinical trial data on CDK 4/6 inhibitors, including efficacy and safety data
- Identify appropriate patient selection for the use of CDK 4/6 inhibitors
- Review the toxicity profiles of CDK 4/6 inhibitors
- Apply strategies to manage neutropenia and other adverse events
- Discuss existing and emerging clinical trial data associated with adverse events of combination therapies using CDK 4/6 inhibitors
- Discuss ways to enhance clinician/patient communication to improve patient outcomes
- Apply shared decision-making strategies in the management of patients with breast cancer
Hyatt Regency Denver Convention Center
Centennial F-G 650
650 15th Street
Denver , CO
United States
P.Kelly Marcom, MD
Linda Sutton, MD
Kerri Dalton, MSN, RN, AOCNS
Melanie Watson, MSN, RN
Richard Finn, MD
Donna Topping PharmD
Available Credit
- 1.50 ACPE - Pharmacist
- 1.50 ANCC
- 1.50 JA Credit - AH